Drug trials fail all the time. What is rare is a failure that costs a company tens of billions of dollars in a single afternoon.
That is what happened to AstraZeneca (AZN) on July 9. One setback wiped out more market value than the stock had lost on any day in years.
For investors, the loss was alarming. But the reason behind the loss was even more concerning.
Wall Street had been counting on this drug to become a major seller, and that trial failure took those hopes off the table in one afternoon.
What AstraZeneca’s trial failure means for the stock
AstraZeneca shares fell after the company said its experimental heart drug Wainua failed the main goal of a late-stage trial, Reuters reported.
The London-listed stock closed down about 7.7%, its worst single day since March 2020 and the biggest drop on the FTSE 100 on Thursday, July 9.
More Health Care Stocks:
- BridgeBio stock jumps after rival heart drug fails key trial
- JPMorgan resets Eli Lilly stock target on drug demand
- JPMorgan resets UnitedHealth stock target for 2026
At its lowest point of the day, the drugmaker had shed roughly £19 billion (about $27 billion) in market value, according to Reuters‘ report.
The drop stands out because AstraZeneca is usually one of Europe’s steadier large-cap names, not a stock that swings like a small company.
Why the Wainua heart trial disappointed investors
Wainua, known generically as eplontersen, is a gene-silencing drug that AstraZeneca co-developed with Ionis Pharmaceuticals (IONS), Reuters reports.
The Phase III trial tested it in a heart condition called ATTR-CM, where a faulty protein builds up in the heart and makes it harder to pump blood.
The study, called CARDIO-TTRansform, did not meet its primary goal.
Adding Wainua to standard care did not significantly cut cardiovascular deaths and repeat heart events over 140 weeks compared with a placebo.
How the trial design blurred the result
Analysts pointed to the trial setup. About 57% of the 1,432 patients were already on a stabilizer drug at enrollment, and roughly another quarter added one during the study.
Because Wainua works by lowering the faulty protein rather than stabilizing it, that overlap made it hard to isolate the drug’s added benefit.
Related: Eli Lilly’s hottest drugs face a quiet new threat
In patients taking Wainua alone, the company said the result looked better, though that subgroup cannot rescue a missed main goal.
How rivals and Ionis partners reacted to the news
The failure did not affect only AstraZeneca. Ionis shares fell about 21%, while companies with approved treatments for the same disease climbed, PharmExec reported.
BridgeBio (BBIO) and Alnylam Pharmaceuticals (ALNY), which already sell ATTR-CM drugs, rose between 6% and 16% as investors saw a less crowded market ahead.
The setback reduced prospects for a drug that analysts had estimated could reach about $2 billion in peak annual sales.
The failure removed those expected future sales from valuation models, which is a big part of why the stock fell so hard.
Why the AstraZeneca selloff was bigger than one drug
The lost revenue alone does not fully explain a move this size. The deeper issue was confidence.
BofA analyst Sachin Jain said the miss came as a surprise, noting that he and other investors had not even debated the odds of a primary endpoint failure given the positive earlier data, PharmExec noted.
Jefferies analysts
called the trial design a possible credibility problem for a management team known for getting trials right.
For a company that investors treat as a gold standard on trial design, a surprise failure affects trust in future readouts, even ones in unrelated areas.
What AstraZeneca investors should watch next
The setback is real, but it does not erase the rest of AstraZeneca’s business. A few things are worth tracking:
Key signals for AstraZeneca stock from here
- Full trial data at the European Society of Cardiology Congress in August, which may show whether the monotherapy signal holds up.
- The July 27 second-quarter earnings report, and whether management touches full-year guidance.
- Wainua’s existing approval for a nerve-damage condition in more than 20 countries, which is unaffected by this trial.
- Broker views on the wider pipeline, with Citi still citing about $46 billion in risk-adjusted peak pipeline sales.
No single trial defines a company this large, yet a surprise failure is a reminder that even strong drugmakers can fail in drug development.
Anyone weighing the stock should size any position to their own risk tolerance and wait for more data before deciding whether the selloff was an overreaction or a warning.
Related: Lilly quietly hands Chinese partner its cancer drug
